Agents that stabilise atherosclerotic plaque

Bibliography

• GLAGOV S, WEISENBERG E, ZARINS CK, STANKUNAVICIUS R, KOLETTIS GJ: Compensatory enlargement of human atherosclerotic coronary arteries. N Engl. J. Med. (1987) 316:1371–1375.
   PubMed Web of Science ®Google Scholar
• •Autopsy study that showed preservation of normal lumen size with plaque build-up.
   Google Scholar
• GIROUD D, LI JM, URBAN P, METER B, RUTISHAUER W: Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiography. Jim. .1 Cardiol (1992) 69(8):729–732.
   Google Scholar
• •Retrospective evaluation of angiography as a poor predictor of subsequent acute MI.
   Google Scholar
• FALK E, SHAH PK, FUSTER V: Coronary plaque disruption. Circulation (1995) 92(3):657–671.
   PubMed Web of Science ®Google Scholar
• TOPOL EJ, NISSEN SE: Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ischemic heart disease. Circulation (1995) 92(8):2333–2342.
   Google Scholar
• ••A review on the dissociation between theangiograrn and clinical outcome.
   Google Scholar
• NISSEN SE, YOCK P: Intravascular ultrasound: novel pathophysiological insights and current clinical applications. Circulation (2001) 103:604–616.
   PubMed Web of Science ®Google Scholar
• TUZCU EM, KAPADIA SR, TUTAR E et al.: High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation (2001) 103(22):2705–2710.
   PubMed Web of Science ®Google Scholar
• •Prevalence of atherosclerosis in young donor hearts.
   Google Scholar
• NISHIOKA T, LUO H, EIGLER NL, BERGLUND H, KIM CJ, SIEGEL RJ: Contribution of inadequate compensatory enlargement to development of human coronary artery stenosis: an in vivo intravascular ultrasound study. I Jim. Coll Cardiol (1996) 27(7):1571–1576.
   PubMed Web of Science ®Google Scholar
• SCHOENHAGEN P, ZIADA KM, KAPADIA SR, CROWE TD, NISSEN SE, TUZCU EM: Extent and direction of arterial remodeling in stable versus unstable coronary syndromes: an intravascular ultrasound study. Circulation (2000) 101(6):598–603.
   PubMed Web of Science ®Google Scholar
• •Intravascular study of the characteristics of an unstable plaque.
   Google Scholar
• GUSSENHOVEN EJ, ESSED CE, LANCEE CT et al.: Arterial wall characteristics determined by intravascular ultrasound imaging: an in vitro study. I Jim. Coll. Cardiol (1989) 14(4):947–952.
   PubMed Web of Science ®Google Scholar
• BOTS ML, HOES AW, KOUDSTAAL PJ, HOFMAN A, GROBBEE DE: Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation (1997) 96(5):1432–1437.
   PubMed Web of Science ®Google Scholar
• BLANKENHORN DH, SELZER RH, CRAWFORD DW et al.: Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two- and four-year reduction of intima-media thickness measured by ultrasound. Circulation (1993) 88(1):20–28.
   Google Scholar
• HODIS HN, MACK WJ, LABREE L et al: The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann. Intern. Med. (1998) 128(4):262–269.
   PubMed Web of Science ®Google Scholar
• HOEG JM: Evaluating coronary heart disease risk. Tiles in the mosaic. "AMA (1997) 277(17):1387–1390.
   Google Scholar
• GREENLAND P, ABRAMS J, AURIGEMMA GP et al.: Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden: Writing Group III. Circulation (2000) 101(1):E16–E22.
   PubMedGoogle Scholar
• SMILDE TJ, WOLLERSHEIM H, VAN LANGEN H, STALENHOEF AF: Reproducibility of ultrasonographic measurements of different carotid and femoral artery segments in healthy subjects and in patients with increased intima-media thickness. Clin. Sci. (fond) (1997) 93(4):317–324.
   PubMed Web of Science ®Google Scholar
• CIULLA MM, PALIOTTI R, FERRERO S, VAND ONE P, MAGRINI F, ZANCHETTI A: Assessment of carotid plaque composition in hypertensive patients by ultrasonic tissue characterization: a validation study. J. Hypertens. (2002) 20(8):1589–1596.
   PubMed Web of Science ®Google Scholar
• CHAMBLESS LE, HEISS G, FOLSOM AR et al: Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Ain. J. Epideiniol (1997) 146(6):483–494.
   PubMed Web of Science ®Google Scholar
• •Observational study showing carotid plaque as a predictor of coronary events.
   Google Scholar
• O'LEARY DH, POLAK JF, KRONMAL RA, MANOLIO TA, BURKE GL, WOLFSON SK Jr: Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl. J. Med. (1999) 340(1):14–22.
   PubMed Web of Science ®Google Scholar
• BURKE AP, TAYLOR A, FARB A, MALCOM GT, VIRMANI R: Coronary calcification: insights from sudden coronary death victims. Z Kardiol (2000) 89\(Suppl. 2):49–53.
   Google Scholar
• O'MALLEY PG, TAYLOR AJ, JACKSON JL, DOHERTY TM, DETRANO RC: Prognostic value of coronary electron-beam computed tomography for coronary heart disease events in asymptomatic populations. Am. J. Cardiol (2000) 85(8):945–948.
   PubMed Web of Science ®Google Scholar
• DETRANO RC, WONG ND, DOHERTY TM et al.: Coronary calcium does not accurately predict near-term future coronary events in high-risk adults. Circulation (1999) 99(20):2633–2638.
   PubMed Web of Science ®Google Scholar
• RAGGI P, CALLISTER TQ, COOIL B et al.: Identification of patients at increased risk of first unheralded acute myocardial infarction by electron-beam computed tomography. Circulation (2000) 101(8):850–855.
   PubMed Web of Science ®Google Scholar
• WORTHLEY SG, HELFT G, FUSTER V et al.: High resolution ex vivo magnetic resonance imaging of in situ coronary and aortic atherosclerotic plaque in a porcine model. Atherosclerosis (2000) 150(2):321–329.
   PubMed Web of Science ®Google Scholar
• FAYAD ZA, FUSTER V, FALL ON JT et al.: Noninvasive in vivo human coronary artery lumen and wall imaging using black-blood magnetic resonance imaging. Circulation (2000) 102(5):506–510.
   Google Scholar
• HELFT G, WORTHLEY SG, FUSTER V et al.: Progression and regression of atherosclerotic lesions: monitoring with serial noninvasive magnetic resonance imaging. Circulation (2002) 105(8):993–998.
   PubMed Web of Science ®Google Scholar
• •Ability of MRI to monitor changes in atherosclerotic plaque composition.
   Google Scholar
• CORTI R, FAYAD ZA, FUSTER V et al.: Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation (2001) 104(3):249–252.
   PubMed Web of Science ®Google Scholar
• ROSENSON RS, TANGNEY CC: Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. "AMA (1998) 279(20):1643–1650.
   PubMed Web of Science ®Google Scholar
• MCFARLANE SI, MUNIYAPPA R, FRANCISCO R, SOWERS JR: Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond. I Clin. Endocrinol Metab. (2002) 87(4):1451–1458.
   PubMed Web of Science ®Google Scholar
• •A thorough review on the beneficial effects of statins that are independent of their classical actions on lipoproteins.
   Google Scholar
• THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S) GROUP: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344(8934):1383–1389.
   PubMed Web of Science ®Google Scholar
• •A landmark study on secondary prevention of CAD.
   Google Scholar
• SACKS FM, PFEFFER MA, MOYE LA et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl. J. Med. (1996) 335(14):1001–1009.
   Google Scholar
• •Another landmark study on secondary prevention of CAD.
   Google Scholar
• SHEPHERD J, COBBE SM, FORD I et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl. J. Med. (1995) 333(20):1301–1307.
   PubMed Web of Science ®Google Scholar
• THE LONG-TERM INTERVENTION WITH PRAVASTATIN IN ISCHAEMIC DISEASE (LIPID) STUDY GROUP: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl. J. Med. (1998) 339(19):1349–1357.
   PubMed Web of Science ®Google Scholar
• DOWNS JR, CLEARFIELD M, WEIS S et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. "AMA (1998) 279(20):1615–1622.
   Google Scholar
• HEART PROTECTION STUDY COLLABORATIVE GROUP: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 360(9326):7–22.
   PubMed Web of Science ®Google Scholar
• SEVER PS, DAHLOF B, POULTER NR et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet (2003) 361:1149–1158.
   PubMed Web of Science ®Google Scholar
• •Randomised study on low-dose statin with reductions in major CV events.
   Google Scholar
• BROWN BG, ZHAO XQ, SACCO DE, ALBERS JJ: Lipid lowering and plaque disruption. Circulation (1993) 87:1781–1791.
   PubMed Web of Science ®Google Scholar
• TAYLOR AJ, KENT SM, FLAHERTY PJ, COYLE LC, MARKWOOD TT, VERNALIS MN: ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation (2002) 106(16):2055–2060.
   PubMed Web of Science ®Google Scholar
• SCHARTL M, BOCKSCH W, KOSCHYK DH et al.: Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation (2001) 104(4):387–392.
   PubMed Web of Science ®Google Scholar
• CORTI R, FUSTER V, FAYAD ZA et al.: Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation (2002) 106(23):2884–2887.
   PubMed Web of Science ®Google Scholar
• WATERS DD, SCHWARTZ GG, OLSSON AG et al.: Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation (2002) 106(13):1690–1695.
   PubMed Web of Science ®Google Scholar
• WEST OF SCOTLAND CORONARY PREVENTION STUDY GROUP: Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation (1998) 97(15):1440–1445.
   PubMed Web of Science ®Google Scholar
• SACKS FM, MOYE LA, DAVIS BR et al.: Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation (1998) 97(15):1446–1452.
   PubMed Web of Science ®Google Scholar
• MULLEN MJ, WRIGHT D, DONALD AE, THORNE S, THOMSON H, DEANFIELD JE: Atorvastatin but not L-arginine improves endothelial function in Type I diabetes mellitus: a double-blind study. J. Am. Coil. Cardiol (2000) 36(2):410–416.
   PubMed Web of Science ®Google Scholar
• TAN KC, CHOW WS,TAM SC, Al VH, LAM CH, LAM KS: Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in Type 2 diabetes mellitus. .1 Clin. Endocrinol Metab. (2002) 87(2):563–568.
   Google Scholar
• JIALAL I, STEIN D, BALIS D, GRUNDY SM, ADAMS-HUET B, DEVARAJ S: Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation (2001) 103(15):1933–1935.
   PubMed Web of Science ®Google Scholar
• ALBERT MA, DANIELSON E, RIFAI N, RIDKER PM: Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. "AMA (2001) 286(1):64–70.
   PubMed Web of Science ®Google Scholar
• EGASHIRA K, NI W, INOUE S et al.: Pravastatin attenuates cardiovascular inflammatory and proliferative changes in a rat model of chronic inhibition of nitric oxide synthesis by its cholesterol-lowering independent actions. Hypertens. Res. (2000) 23(4):353–358.
   PubMed Web of Science ®Google Scholar
• PRUEFER D, SCALIA R, LEFER AM: Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. Arterioscler. Thromb. Vasc. Biol. (1999) 19(12):2894–2900.
   PubMed Web of Science ®Google Scholar
• KINLAY S, TIMMS T, CLARK M et al.: Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia. Am. J. Cardiol. (2002) 89(10):1205–1207.
   PubMed Web of Science ®Google Scholar
• WAGNER AH, KOHLER T, RUCKSCHLOSS U, JUST I, HECKER M: Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arteriosc/er. DIFOR1/1. V3SC. Biol. (2000) 20(1):61–69.
   Google Scholar
• WASSMANN S, LAUFS U, BAUMER AT et al.: HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension (2001) 37(6):1450–1457.
   PubMed Web of Science ®Google Scholar
• VASA M, FICHTLSCHERER S, ADLER K et al: Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation (2001) 103(24)2885–2890.
   Google Scholar
• SHINTANI S, MUROHARA T, IKEDA H et al.: Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation (2001) 103(23):2776–2779.
   PubMed Web of Science ®Google Scholar
• LLEVADOT J, MURASAWA S, KUREISHI Y et al.: HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. Clin. Invest. (2001) 108(3):399–405.
   Google Scholar
• COLLINS R, ARMITAGE J, PARISH S, SLEIGH P, PETO R, HEART PROTECTION STUDY COLLABORATIVE GROUP: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet (2003) 361(9374):2005–2016.
   PubMed Web of Science ®Google Scholar
• BRAUNWALD E, ANTMAN EM, BEASLEY JW et al.: Committee on the Management of Patients With Unstable Angina. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). I Am. Coll Cardiol (2002) 40(7):1366–1374.
   Google Scholar
• FRISHMAN WH, HERSHMAN D: Beta-adrenergic blocking drugs in cardiac disorders. In: Cardiovascular Drug Therapy FH Messerli (Ed.), WB Saunders Co., Philadelphia, PA, USA (1996):465–474.
   Google Scholar
• KAPLAN JR, MANUCK SB: Antiatherogenic effects of beta-adrenergic blocking agents: theoretical, experimental, and epidemiologic considerations. Am. Heart J. (1994) 128(6, Pt 2):1316–1328.
   Google Scholar
• KAPLAN JR, MANUCK SB, ADAMS MR, CLARKSON TB: The effects of beta-adrenergic blocking agents on atherosclerosis and its complications. Eur. Heart J. (1987) 8(9):928–944.
   PubMed Web of Science ®Google Scholar
• BEERE PA, GLAGOV S, ZARINS CK: Retarding effect of lowered heart rate on coronary atherosclerosis. Science (1984) 226(4671):180–182.
   PubMed Web of Science ®Google Scholar
• HEDBLAD B, WIKSTRAND J, JANZON L, VVEDEL H, BERGLUND G: Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation (2001) 103(13):1721–1726.
   PubMed Web of Science ®Google Scholar
• WIKLUND 0, HULTHE J, WIKSTRAND J, SCHMIDT C, OLOFSSON SO, BONDJERS G: Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. Stroke (2002) 33(2):572–577.
   PubMed Web of Science ®Google Scholar
• BLOT WJ, LI JY, TAYLOR PR et al.: Nutrition intervention trials in Limdan, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population." Natl. Cancer Inst. (1993) 85(18):1483–1492.
   Google Scholar
• (NO AUTHORS LISTED): Dietary supplementation with N-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial: Gruppo Italian° per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet (1999) 354(9177):447–455.
   PubMed Web of Science ®Google Scholar
• LONN E, YUSUF S, DZAVIK Vet al.: Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation (2001) 103(7):919–925.
   Google Scholar
• •Study of vitamin E in a high-risk population with vascular disease.
   Google Scholar
• STEPHENS NG, PARSONS A, SCHOFIELD PM, KELLY F, CHEESEMAN K, MITCHINSON MJ: Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet (1996) 347(9004):781–786.
   PubMed Web of Science ®Google Scholar
• HEART PROTECTION STUDY COLLABORATIVE GROUP: MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 360(9326):23–33.
   PubMed Web of Science ®Google Scholar
• •Study of vitamin E in a high-risk population with vascular disease.
   Google Scholar
• THE ALPHA-TOCOPHEROL BETA CAROTENE CANCER PREVENTION STUDY GROUP: The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl. J. Med. (1994) 330:1029–1035.
   PubMed Web of Science ®Google Scholar
• BROWN BG, ZHAO XQ, CHAIT A et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl. J. Med. (2001) 345(22):1583–1592.
   PubMed Web of Science ®Google Scholar
• CHEUNG MC, ZHAO XQ, CHAIT A, ALBERS JJ, BROWN BG: Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL. Arteriesc/er. Thremb. Vase. Biol. (2001) 21(8):1320–1326.
   PubMed Web of Science ®Google Scholar
• LIBBY P, SIMON DI: Inflammation and thrombosis: the clot thickens. Circulation (2001) 103(13):1718–1720.
   PubMed Web of Science ®Google Scholar
• SCHIEFFER B, SCHIEFFER E, HILFIKER-KLEINER D et al.: Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation (2000) 101(12):1372–1378.
   PubMed Web of Science ®Google Scholar
• MANCINI GB, HENRY GC, MACAYA C et al.: Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) study. Circulation (1996) 94(3):258–265.
   PubMed Web of Science ®Google Scholar
• PITT B, O'NEILL B, FELDMAN R et al.: The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am.j Cardiol. (2001) 87(9):1058–1063.
   Google Scholar
• MEURICE T, BAUTERS C, HERMANT X et al.: Effect of ACE inhibitors on angiographic restenosis after coronary stenting (PARIS): a randomised, double-blind, placebo-controlled trial. Lancet (2001) 357(9265):1321–1324.
   PubMed Web of Science ®Google Scholar
• YUSUF S, SLEIGHT P, POGUE J, BOSCH J, DAVIES R, DAGENAIS G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl. Med. (2000) 342(3):145–153.
   PubMed Web of Science ®Google Scholar
• ••Pivotal study of ACEI on clinical outcomesin a high-risk group of patients.
   Google Scholar
• PROGRESS COLLABORATIVE GROUP: Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. Eur: Heart (2003) 24(5):475–484.
   PubMed Web of Science ®Google Scholar
• PITT B, BYINGTON RP, FURBERG CD et al.: Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation (2000) 102(13):1503–1510.
   PubMed Web of Science ®Google Scholar
• JORGENSEN B, SIMONSEN S, ENDRESEN K et al.: Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES). jAm. Coll. Cardiol. (2000) 35(3):592–599.
   PubMed Web of Science ®Google Scholar
• ZANCHETTI A, BOND MG, HENNIG M et al.: Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation (2002) 106(19):2422–2427.
   PubMed Web of Science ®Google Scholar
• HANSSON L, ZANCHETTI A, CARRUTHERS SG et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet (1998) 351(9118):1755–1762.
   PubMed Web of Science ®Google Scholar
• STAESSEN JA, FAGARD R, THIJS L et al.: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet (1997) 350(9080):757–764.
   PubMed Web of Science ®Google Scholar
• LOSORDO DW, KEARNEY M, KIM EA, JEKANOWSKI J, ISNERJM: Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation (1994) 89(4):1501–1510.
   PubMed Web of Science ®Google Scholar
• BARRETT-CONNOR E, GRADY D: Hormone replacement therapy, heart disease, and other considerations. Ann. Rev Public Health (1998) 19:55–72.
   PubMed Web of Science ®Google Scholar
• LASSILA HC, TYRRELL KS, MATTHEWS KA, WOLFSON SK, KULLER LH: Prevalence and determinants of carotid atherosclerosis in healthy postmenopausal women. Stroke (1997) 28(3):513–517.
   PubMed Web of Science ®Google Scholar
• WATERS DD, ALDERMAN EL, HSIA J et al.: Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA (2002) 288(19):2432–2440.
   PubMed Web of Science ®Google Scholar
• HULLEY S, GRADY D, BUSH T et al.: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA (1998) 280(7):605–613.
   Google Scholar
• ••A study of oestrogen on secondaryprevention of coronary disease.
   Google Scholar
• MANSON JE, HSIA J, JOHNSON KC et al.: Estrogen plus progestin and the risk of coronary heart disease. N Engl. I Med. (2003) 349(6):523–534.
   PubMed Web of Science ®Google Scholar
• ••A study of oestrogen on secondaryprevention of coronary disease.
   Google Scholar
• MANSON JE, MARTIN KA: Clinical practice. Postmenopausal hormone-replacement therapy. N Engl. I Med. (2001) 345(1):34–40.
   PubMedGoogle Scholar
• RUTQVIST LE, MATTSSON A: Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. .1. Natl. Cancer Inst. (1993) 85(17):1398–1406.
   Google Scholar
• COSTANTINO JP, KULLER LH, IVES DG, FISHER B, DIGNAM J: Coronary heart disease mortality and adjuvant tamoxifen therapy. j. Nati Cancer Inst. (1997) 89(11):776–782.
   PubMed Web of Science ®Google Scholar
• LOVE RR, WIEBE DA, FEYZI JM, NEWCOMB PA, CHAPPELL RJ: Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J. Natl. Cancer Inst. (1994) 86(20):1534–1539.
   PubMed Web of Science ®Google Scholar
• GREY AB, STAPLETON JP, EVANS MC, REID IR: The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin. Endocrinol. Metab. (1995) 80(11):3191–3195.
   PubMed Web of Science ®Google Scholar
• CLARKE SC, SCHOFIELD PM, GRACE AA, METCALFE JC, KIRSCHENLOHR HL: Tamoxifen effects on endothelial function and cardiovascular risk factors in men with advanced atherosclerosis. Circulation (2001) 103(11):1497–1502.
   PubMed Web of Science ®Google Scholar
• CUSHMAN M, COSTANTINO JP, TRACY RP et al.: Tamoxifen and cardiac risk factors in healthy women: Suggestion of an anti-inflammatory effect. Arteriosclec Tbromb. Vasc. Biol. (2001) 21(2):255–261.
   PubMed Web of Science ®Google Scholar
• BARRETT-CONNOR E, GRADY D, SASHEGYI A et al.: Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA (2002) 287(7):847–857.
   PubMed Web of Science ®Google Scholar
• CERNE A, KRANJEC I: Atherosclerotic burden in coronary and peripheral arteries in patients with first clinical manifestation of coronary artery disease. Heart Vessels (2002) 16(6):217–226.
   PubMed Web of Science ®Google Scholar
• ELLIS S, ALDERMAN E, CAIN K, FISHER L, SANDERS W, BOURASSA M: Prediction of risk of anterior myocardial infarction by lesion severity and measurement method of stenoses in the left anterior descending coronary distribution: a CASS Registry Study. I Am. Coll. Cardiol (1988) 11(5):908–916.
   PubMed Web of Science ®Google Scholar
• ••Study showing the risk of MI and lesionseverity.
   Google Scholar
• VAN DER WAL AC, BECKER AE, VAN DER LOOS CM, DAS PK: Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation (1994) 89(1):36–44.
   PubMed Web of Science ®Google Scholar
• BLANKENHORN DH, HODIS HN: George Lyman Duff Memorial Lecture. Aerial imaging and atherosclerosis reversal. Arterioscler. Thromb. (1994) 14(2):177–192.
   PubMedGoogle Scholar
• LEVINE GN, KEANEY JF Jr, VITA JA: Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl. I Med. (1995) 332(8):512–521.
   PubMed Web of Science ®Google Scholar
• RICHARDSON PD, DAVIES MJ, BORN GV: Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet (1989) 2(8669):941–944.
   PubMed Web of Science ®Google Scholar
• CHENG GC, LOREE HM, KAMM RD, FISHBEIN MC, LEE RT: Distribution of circumferential stress in ruptured and stable atherosclerotic lesions. A structural analysis with histopathological correlation. Circulation (1993) 87(4):1179–1187.
   Google Scholar
• FONAROW GC, GAWLINSKI A, MOUGHRABI S, TILLISCH JH: Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am. .1. Cardiol (2001) 87(7):819–822.
   Google Scholar
• ••Outcomes in post-MI patients.
   Google Scholar